GanedenBC30™ cell wall and metabolites: Anti-inflammatory and immune modulating effects in vitro

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Jensen, Gitte S ^a   Benson, Kathleen F ^a   Carter, Steve G ^a   Endres, John R ^b  

^a NIS Labs   (United States)

^b AIBMR Life Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GANEDENBC30; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROBIOTIC AGENT; PTA 6086; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIUM CULTURE; CD3+ T LYMPHOCYTE; CELL ISOLATION; CELL METABOLISM; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; IN VITRO STUDY; MIGRATION INHIBITION; NATURAL KILLER CELL; OXIDATIVE STRESS; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; BACILLUS; BIOSYNTHESIS; CELL MOTION; CELL WALL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL; NEUTROPHIL;

ANTI-INFLAMMATORY AGENTS; BACILLUS; CELL MOVEMENT; CELL WALL; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEUTROPHILS; PROBIOTICS;

EID: 77952271665     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-15     Document Type: Article

References (35)

1. Rescigno M, Lopatin U, Chieppa M. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. Curr Opin Immunol 2008, 20:669-75. 10.1016/j.coi.2008.09.007, 18852045.
2. Ruemmele FM, Bier D, Marteau P, Rechkemmer G, Bourdet-Sicard R, Walker WA, Goulet O. Clinical evidence for immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009, 48:126-41. 10.1097/MPG.0b013e31817d80ca, 19179874.
3. Kim YS, Young MR, Bobe G, Colburn NH, Milner JA. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res (Phila Pa) 2009, 2:200-8.
4. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-31. 10.1038/nature05414, 17183312.
5. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify?. Am J Med 2006, 119:e17-28. 10.1016/j.amjmed.2005.06.057, 16443421.
6. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-35. 10.1016/j.cell.2006.02.016, 16497591.
7. Hormannsperger G, Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: Clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol 2010, 300(1):63-73. 10.1016/j.ijmm.2009.08.006, 19828372.
8. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008, 111:1-66.
9. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300-10. 10.1002/ibd.20602, 18626975.
10. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009, 31:368-76. 10.1016/j.immuni.2009.08.009, 19766080.
11. Dominguez-Bello MG, Blaser MJ. Do you have a probiotic in your future?. Microbes Infect 2008, 10:1072-6. 10.1016/j.micinf.2008.07.036, 2613679, 18762263.
12. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001, 73:399S-405S.
13. Graff S, Chaumeil JC, Boy P, Lai-Kuen R, Charrueau C. Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition. Biol Pharm Bull 2008, 31:266-72. 10.1248/bpb.31.266, 18239285.
14. Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol 2006, 7:73-89.
15. Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol 2002, 68:2344-52. 10.1128/AEM.68.5.2344-2352.2002, 127533, 11976107.
16. Endres JR, Clewell A, Jade KA, Farber T, Hauswirth J, Schauss AG. Safety assessment of a proprietary preparation of a novel Probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol 2009, 47:1231-8. 10.1016/j.fct.2009.02.018, 2726964, 19248815.
17. Sanders ME, Morelli L, Tompkins TA. Sporeformers as human probiotics: Bacillus, Sporolactobacillus, and Brevibacillus. Compr Rev Food Sci Food Saf 2003, 2:101-110.
18. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009, 121:119-24. 10.3810/pgm.2009.03.1984, 19332970.
19. Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 2009, 121:114-8. 10.3810/pgm.2009.03.1971, 19332969.
20. Ostad SN, Salarian AA, Ghahramani MH, Fazeli MR, Samadi N, Jamalifar H. Live and heat-inactivated lactobacilli from feces inhibit Salmonella typhi and Escherichia coli adherence to Caco-2 cells. Folia Microbiol (Praha) 2009, 54:157-60. 10.1007/s12223-009-0024-7, 19418255.
21. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008, 10:37-54.
22. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136:65-80. 10.1053/j.gastro.2008.10.080, 19026645.
23. Draing C, Sigel S, Deininger S, Traub S, Munke R, Mayer C, Hareng L, Hartung T, von Aulock S, Hermann C. Cytokine induction by Gram-positive bacteria. Immunobiology 2008, 213:285-96. 10.1016/j.imbio.2007.12.001, 18406374.
24. Li WI, Brackett BG, Halper J. Culture supernatant of Lactobacillus acidophilus stimulates proliferation of embryonic cells. Exp Biol Med (Maywood) 2005, 230:494-500.
25. Honzel D, Carter SG, Redman KA, Schauss AG, Endres JR, Jensen GS. Comparison of Chemical and Cell-Based Antioxidant Methods for Evaluation of Foods and Natural Products: Generating Multifaceted Data by Parallel Testing Using Erythrocytes and Polymorphonuclear Cells. J Agric Food Chem 2008, 56:8319-8325. 10.1021/jf800401d, 18717566.
26. Jensen GS, Patterson KM, Barnes J, Schauss AG, Beaman R, Reeves SG, Robinson LE. A Double-Blind Placebo-Controlled, Randomized Pilot Study: Consumption of a High-Metabolite Immunogen from Yeast Culture has Beneficial Effects on Erythrocyte Health and Mucosal Immune Protection in Healthy Subjects. Open Nutrition Journal 2008, 2:68-75.
27. Hart AN, Zaske LA, Patterson KM, Drapeau C, Jensen GS. Natural killer cell activation and modulation of chemokine receptor profile in vitro by an extract from the cyanophyta Aphanizomenon flos-aquae. J Med Food 2007, 10:435-41. 10.1089/jmf.2007.401, 17887936.
28. Jensen GS, Hart AN, Schauss AG. An antiinflammatory immunogen from yeast culture induces activation and alters chemokine receptor expression on human natural killer cells and B lymphocytes in vitro. Nutrition Research 2007, 27:327-335.
29. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22. 10.1016/j.jim.2004.08.008, 15604012.
30. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 2003, 207:85-93. 10.1078/0171-2985-00219, 12675266.
31. Harris G, KuoLee R, Chen W. Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol 2006, 12:2149-60.
32. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002, 8:567-73. 10.1038/nm0602-567, 12042806.
33. Nicholson LB, Raveney BJ, Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr Mol Med 2009, 9:23-9. 10.2174/156652409787314499, 19199939.
34. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-9. 10.1016/j.cgh.2006.03.028, 16716759.
35. Moretto MM, Weiss LM, Combe CL, Khan IA. IFN-gamma-producing dendritic cells are important for priming of gut intraepithelial lymphocyte response against intracellular parasitic infection. J Immunol 2007, 179:2485-92.